Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on March 8, 2018. The filing announces the company's financial results for the year and quarter ended December 31, 2017. Seres Therapeutics is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) and a corporate slide presentation (Exhibit 99.2) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document confirms that updated cash guidance was included in the attached slide presentation.
Material Changes and Operational Updates
- Financial Results: The company announced results for the full year and fourth quarter of 2017.
- Clinical Progress: The filing references preliminary results of the Phase 1b study of the company's product candidate, SER-262, included in the attached slide presentation.
- Strategic Updates: Strategic and operational updates were posted to the company's investor relations website.
Guidance, Outlook, and Risks
Management provided updated cash guidance as part of the corporate slide presentation furnished with this report. The filing explicitly states that the information contained in the press release and slide presentation is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2017.
- Examine Exhibit 99.2 (Corporate Slide Presentation) for the updated cash runway and specific details on the SER-262 Phase 1b study results.
- Verify the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.